Ownership history in SWS Partners Β· 16 quarters on record
This page tracks every 13F SEC filing in which SWS Partners reported a position in Guardant Health Inc (GH). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π SWS Partners outperformed the S&P 500 by +21.5% annually on this GH position. Timing score: 50% (7/14 decisions correct). Average cost basis: $35.96. Maximum drawdown during holding period: β68.9%.
π₯ Exceptional β beat the S&P 500 by 21.5% per year on this position.
15 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
7 of 14 add/trim decisions correct
Best entry: $22.94 (2024 Q3) Β· Worst: $66.24 (2022 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
10 adds Β· 5 trims. Bought during 5 of 7 down-price quarters. π More buys than sells across the holding period.
π SWS Partners has been actively increasing its GH allocation β a bullish signal from insiders.
Currently 1.9% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size